Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DBE87X
|
|||
| Drug Name |
MRG-110
|
|||
| Drug Type |
Oligonucleotide
|
|||
| Indication | Heart failure [ICD-11: BD10-BD13] | Phase 1 | [1] | |
| Company |
miRagen Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | microRNA hsa-miR-92 (MIR92) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03603431) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers. U.S. National Institutes of Health. | |||
| REF 2 | Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study. Nucleic Acid Ther. 2020 Dec;30(6):335-345. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.